Reid Merryman, Md

This study is testing whether a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—is safe and effective for people whose follicular or marginal zone lymphoma has come back or hasn't responded to prior treatments. About 45 participants will receive the treatment …

This study is testing a new two-drug combination for adults who have not yet received treatment for follicular lymphoma, a type of slow-growing blood cancer. The goal is to see if adding a newer drug (epcoritamab) to a standard one (rituximab) is safe and more effective at contro…